Should I buy or sell OmniAb stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OABI shares. View OABI analyst ratings or view top-rated stocks .

What is OmniAb's stock price target for 2024?

8 equities research analysts have issued 1-year price objectives for OmniAb's stock. Their OABI share price targets range from $6.00 to $13.00. On average, they anticipate the company's share price to reach $9.75 in the next twelve months. This suggests a possible upside of 107.9% from the stock's current price. View analysts price targets for OABI or view top-rated stocks among Wall Street analysts .

How have OABI shares performed in 2023?

OmniAb's stock was trading at $3.60 on January 1st, 2023. Since then, OABI shares have increased by 30.3% and is now trading at $4.69. View the best growth stocks for 2023 here .

When is OmniAb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our OABI earnings forecast .

How were OmniAb's earnings last quarter?

OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.02. The firm had revenue of $5.48 million for the quarter, compared to analysts' expectations of $11.37 million. OmniAb had a negative trailing twelve-month return on equity of 8.88% and a negative net margin of 45.99%.

Who are OmniAb's major shareholders?

OmniAb's stock is owned by a number of retail and institutional investors. Top institutional investors include Chicago Capital LLC (2.75%), William Blair Investment Management LLC (2.46%), Rubric Capital Management LP (2.45%), Rubric Capital Management LP (2.45%), Rice Hall James & Associates LLC (2.39%) and Private Management Group Inc. (2.30%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr. View institutional ownership trends .

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

OmniAb Stock Price, News & Analysis (NASDAQ:OABI)

$4.79

+0.08 (+1.70%)

(As of 02:42 PM ET)

Compare

Today's Range: $4.58
▼
$4.80
50-Day Range: $4.23
▼
$5.31
52-Week Range: $3.06
▼
$5.97

Volume: 414,302 shs
Average Volume: 568,114 shs
Market Capitalization: $556.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.75

OmniAb MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 107.9% Upside
$9.75 Price Target
Short Interest: Healthy
4.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.50
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$405,650 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.52) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

259th out of 948 stocks

Commercial Physical Research Industry

4th out of 11 stocks

3.5

Analyst's Opinion

Consensus Rating
OmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.75, OmniAb has a forecasted upside of 107.9% from its current price of $4.69.
Amount of Analyst Coverage
OmniAb has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.61% of the float of OmniAb has been sold short.
Short Interest Ratio / Days to Cover
OmniAb has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
Change versus previous month
Short interest in OmniAb has recently decreased by 11.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
OmniAb does not currently pay a dividend.
Dividend Growth
OmniAb does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OABI.

3.1

News and Social Media Coverage

News Sentiment
OmniAb has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for OmniAb this week, compared to 1 article on an average week.
Search Interest
1 people have searched for OABI on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added OmniAb to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OmniAb insiders have bought more of their company's stock than they have sold. Specifically, they have bought $405,650.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.00% of the stock of OmniAb is held by insiders.
Percentage Held by Institutions
58.73% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OmniAb are expected to grow in the coming year, from ($0.52) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OmniAb is -15.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OmniAb is -15.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OmniAb has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OmniAb Stock (NASDAQ:OABI)

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OABI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OABI Stock News Headlines

December 5, 2023 | finance.yahoo.com

Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 30%?

December 2, 2023 | americanbankingnews.com

OmniAb (NASDAQ:OABI) Research Coverage Started at Royal Bank of Canada

December 5, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

November 20, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript

November 15, 2023 | finance.yahoo.com

Matthew Foehr Bought 4.1% More Shares In OmniAb

November 14, 2023 | seekingalpha.com

OmniAb, Inc. 2023 Q1 - Results - Earnings Call Presentation

November 14, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Slashed Next Year's Revenue Estimates By 14%

November 14, 2023 | finance.yahoo.com

Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares

December 5, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

November 11, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Technology Stocks: Airgain (AIRG), OmniAb (OABI) and Par Technology (PAR)

November 9, 2023 | finance.yahoo.com

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual Event

November 9, 2023 | finance.yahoo.com

OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss

November 9, 2023 | finance.yahoo.com

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

November 2, 2023 | finance.yahoo.com

OmniAb to Participate in Two Investor Conferences in November

November 1, 2023 | finance.yahoo.com

OmniAb Appoints Steve Love to its Board of Directors

October 31, 2023 | finance.yahoo.com

OmniAb Announces Agenda for its Research & Technology Virtual Event

October 12, 2023 | finance.yahoo.com

OmniAb to Hold Research & Technology Virtual Event on November 9

September 26, 2023 | msn.com

Immunovant drives OmniAb higher after data update; argenx slips

September 25, 2023 | msn.com

OmniAb: Hold For Growth

September 17, 2023 | seekingalpha.com

OABIW OmniAb, Inc. WT EXP 110127

September 5, 2023 | finance.yahoo.com

OmniAb to Participate in Two Investor Conferences in September

August 18, 2023 | finance.yahoo.com

OmniAb President Acquires 2.0% More Stock

August 16, 2023 | finance.yahoo.com

Need To Know: Analysts Just Made A Substantial Cut To Their OmniAb, Inc. (NASDAQ:OABI) Estimates

August 15, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript

August 13, 2023 | markets.businessinsider.com

Truist Financial Remains a Buy on OmniAb (OABI)

August 13, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Technology Companies: Evolv Technologies Holdings (EVLV), Viavi Solutions (VIAV) and OmniAb (OABI)

See More Headlines

Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OABI
CUSIP: N/A
CIK: 1846253
Web: www.omniab.com
Phone: 510-250-7800
Fax: N/A
Employees: 95
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.75
High Stock Price Target: $13.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +107.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,330,000.00
Net Margins: -45.99%
Pretax Margin: -53.64%
Return on Equity: -8.88%
Return on Assets: -7.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.26
Quick Ratio: 4.26

Sales & Book Value

Annual Sales: $59.08 million
Price / Sales: 9.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.96 per share
Price / Book: 1.59

Miscellaneous

Outstanding Shares: 116,240,000
Free Float: 108,101,000
Market Cap: $547.49 million
Optionable: Not Optionable
Beta: -0.40

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Matthew W. Foehr (Age 50)
President, CEO & Director
Comp: $967.72k
Mr. Kurt A. Gustafson (Age 55)
Executive VP of Finance & CFO
Comp: $558.48k
Mr. Charles S. Berkman J.D. (Age 54)
Chief Legal Officer & Secretary
Comp: $734.33k
Ms. Cia McCaffrey
Vice President of People & Talent
Dr. Bill Harriman Ph.D.
Senior Vice President of Antibody Discovery
Ms. Marie-Cecile van de Lavoir D.V.M.
Ph.D., Senior Vice President of Technical Operations & Genetics
Dr. Christel Iffland Ph.D.
Senior Vice President of Antibody Technologies
Dr. Douglas S. Krafte Ph.D. (Age 65)
Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
Ms. Donna Ventura CPA
Senior Vice President of Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OABI Stock Analysis - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OABI shares.
View OABI analyst ratings or view top-rated stocks.
What is OmniAb's stock price target for 2024?: 8 equities research analysts have issued 1-year price objectives for OmniAb's stock. Their OABI share price targets range from $6.00 to $13.00. On average, they anticipate the company's share price to reach $9.75 in the next twelve months. This suggests a possible upside of 107.9% from the stock's current price.
View analysts price targets for OABI or view top-rated stocks among Wall Street analysts.
How have OABI shares performed in 2023?: OmniAb's stock was trading at $3.60 on January 1st, 2023. Since then, OABI shares have increased by 30.3% and is now trading at $4.69.
View the best growth stocks for 2023 here.
When is OmniAb's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our OABI earnings forecast.

How were OmniAb's earnings last quarter?: OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.02. The firm had revenue of $5.48 million for the quarter, compared to analysts' expectations of $11.37 million. OmniAb had a negative trailing twelve-month return on equity of 8.88% and a negative net margin of 45.99%.
Who are OmniAb's major shareholders?: OmniAb's stock is owned by a number of retail and institutional investors. Top institutional investors include Chicago Capital LLC (2.75%), William Blair Investment Management LLC (2.46%), Rubric Capital Management LP (2.45%), Rubric Capital Management LP (2.45%), Rice Hall James & Associates LLC (2.39%) and Private Management Group Inc. (2.30%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr.
View institutional ownership trends.
How do I buy shares of OmniAb?: Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OABI) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

OmniAb Stock Price, News & Analysis (NASDAQ:OABI)

OmniAb MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About OmniAb Stock (NASDAQ:OABI)

OABI Stock Price History

OABI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OABI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™